Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Biosens Bioelectron. 2020 Jan 15;148:111833. doi: 10.1016/j.bios.2019.111833. Epub 2019 Nov 1.
More recently, detection of circulating tumor cells (CTCs) has been considered as an appealing prognostic and diagnostic approach for cancer patients. CTCs as a type of tumor-derived cells are secreted by the tumor and released into the blood circulation. Since the migration of CTCs is an early event in cancer progression, patients who still have tumor-free lymph nodes have to be well examined for the CTCs presence in their blood circulation. Nowadays, there is a broad range of detection methods available to identify CTCs. As artificial RNA oligonucleotides or single-stranded DNA with receptor and catalytic characteristics, aptamers have been standing out, owing to their target-induced conformational modifications, elevated stability, and target specificity to be implemented in biosensing techniques. To date, several sensitivity-enhancement methods alongside smart nanomaterials have been used for the creation of new aptasensors to address the limit of detection (LOD), and improve the sensitivity of numerous analyte identification methods. The present review article supports a focused overview of the recent studies in the identification and quantitative determination of CTCs by aptamer-based biosensors and nanobiosensors.
最近，循环肿瘤细胞（CTC）的检测已被认为是一种有吸引力的癌症患者预后和诊断方法。CTC 是一种肿瘤衍生细胞，由肿瘤分泌并释放到血液循环中。由于 CTC 的迁移是癌症进展的早期事件，因此仍然没有肿瘤淋巴结的患者必须对其血液中 CTC 的存在进行仔细检查。如今，有广泛的检测方法可用于识别 CTC。由于人工 RNA 寡核苷酸或具有受体和催化特性的单链 DNA，适体因其靶标诱导的构象修饰、稳定性提高和对生物传感技术的靶标特异性而脱颖而出。迄今为止，已经使用了几种灵敏度增强方法和智能纳米材料来创建新的适体传感器，以解决检测限（LOD）问题，并提高许多分析物识别方法的灵敏度。本文综述了基于适体的生物传感器和纳米生物传感器在鉴定和定量测定 CTC 方面的最新研究。
